InsidersTradesSigma
Track the 健帆生物 stock price and the full insider trade history of the company, a listed issuer based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 健帆生物 has logged 6 public disclosures. Market capitalisation: €14.7bn. The latest transaction was reported on 13 January 2023 (Sale). Among the most active insiders: 何小莲. The full history is openly available.
6
Insider Decl.
n/a
Thresholds
€13m
2 ops.
Buy Volume
€911,927
4 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,650 of 28,803 companies
63.2
score / 100
Value47
Quality79
FCF yld3.7%
Earn yld3.6%
EV/EBITDA19.1x
ROE16%
Gross mgn79%
Net mgn26%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 January 2023
Declarations6 total
6 of 6 declarations
About 健帆生物
健帆生物 is a company focused on the health and pharmaceutical sector, specializing in the development of biological solutions. It is listed on the XSHE market.